Literature DB >> 32142196

Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres.

Lynn M Malec1,2, Stacy E Croteau3, Michael U Callaghan4, Robert F Sidonio5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32142196     DOI： 10.1111/hae.13943

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  6 in total

Review 1.  How do we optimally utilize factor concentrates in persons with hemophilia?

Authors:  Ming Y Lim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?

Authors:  Patrick Ellsworth; Alice Ma
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 3.  IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data.

Authors:  Miguel Escobar; Maria Elisa Mancuso; Cedric Hermans; Cindy Leissinger; Wilfried Seifert; Yanyan Li; William McKeand; Johannes Oldenburg
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.241

Review 4.  Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review.

Authors:  Samantha Pasca; Ezio Zanon
Journal:  Drug Des Devel Ther       Date:  2022-09-15       Impact factor: 4.319

Review 5.  Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities-a practical review.

Authors:  Cedric Hermans; Gerry Dolan
Journal:  Ther Adv Hematol       Date:  2020-10-20

6.  Optimal trough levels in haemophilia B: Raising expectations.

Authors:  Christopher Walsh; Michiel Coppens; Miguel Escobar; Michael Wang
Journal:  Haemophilia       Date:  2020-08-25       Impact factor: 4.287
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.